- Home
- WNEB vs LRMR Comparison
WNEB vs LRMR Comparison
Compare WNEB & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | LRMR |
|---|---|---|
| Founded | 1853 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.5M | 260.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WNEB | LRMR |
|---|---|---|
| Price | $14.16 | $3.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.00 | ★ $16.50 |
| AVG Volume (30 Days) | 56.2K | ★ 1.2M |
| Earning Date | 01-27-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 34.36 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $82,278,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.32 | N/A |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $7.63 | $1.61 |
| 52 Week High | $14.00 | $5.37 |
Technical Indicators
Market Signals| Indicator | WNEB | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 71.61 | 42.14 |
| Support Level | $13.02 | $3.05 |
| Resistance Level | $13.80 | $3.61 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 87.43 | 36.42 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.